


## BRD4 Inhibitor-15

<b>Cat. No.:</b>	HY-143235
<b>CAS No.:</b>	2761366-60-1
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>21</sub> N <sub>3</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	359.42
<b>Target:</b>	Epigenetic Reader Domain; Apoptosis; Bcl-2 Family; Caspase; c-Myc
<b>Pathway:</b>	Epigenetics; Apoptosis
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	BRD4 Inhibitor-15 (compound 13) is a potent BRD4 inhibitor, with an IC <sub>50</sub> of 18 nM. BRD4 Inhibitor-15 induces apoptosis of 22RV1 cells by regulating Bcl-2/Bax proteins and activating caspase-3 signaling pathway. BRD4 Inhibitor-15 down-regulates the c-Myc level in 22RV1 cells. BRD4 Inhibitor-15 can be used for prostate cancer research <sup>[1]</sup> .			
<b>IC<sub>50</sub> &amp; Target</b>	BRD4(1)	BRD4(1)	Bcl-2	Bax
	18 ± 1.1 nM (IC <sub>50</sub> )	18 ± 1.1 nM (IC <sub>50</sub> )		
	Caspase-3	Procaspase-3		
<b>In Vitro</b>	BRD4 Inhibitor-15 (compound 13) shows potent anti-proliferative activity against enzalutamide-resistant 22RV1 cells and LNCap cells, with IC <sub>50</sub> values of 8.27 ± 0.28 and 7.33 ± 0.49 μM, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

### REFERENCES

[1]. Jiang W, et al. Design, synthesis, and evaluation of novel pyridone derivatives as potent BRD4 inhibitors for the potential treatment of prostate cancer. *Bioorg Chem.* 2022 Feb;119:105575.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA